Fabre-Kramer Pharmaceuticals
Fabre-Kramer Pharmaceuticals, Inc.
5847 San Felipe St,
Houston, TX 77057
Phone: (713) 975-6900Website: https://fabrekramer.com/
Latest news
- FDA Approves Exxua (gepirone) for the Treatment of Major Depressive Disorder in Adults
28 September 2023 - Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of PDUFA Regulatory Action Date
24 January 2023 - Fabre-Kramer Submits NDA Amendment for Exxua™ for Treatment of Major Depressive Disorder
4 January 2023 - FDA Rules Favorably On Efficacy Of Travivo (Gepirone ER) For Treatment Of Major Depressive Disorder
17 March 2016 - Fabre-Kramer Looks Forward to FDA's Decision on Gepirone ER for the Treatment of Major Depressive Disorder
2 December 2015 - Fabre Kramer Pharmaceuticals Receives Decision From FDA on GepironeER for Major Depressive Disorder
5 November 2007 - Fabre-Kramer Refiles Gepirone ER with the FDA for the Treatment ofMajor Depressive Disorder
8 May 2007
Drugs Associated with Fabre-Kramer Pharmaceuticals, Inc.
Fabre-Kramer Pharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.